(“Sodium-Glucose Transporter 2 Inhibitors”[Mesh] OR “SGLT2 inhibitors” OR empagliflozin OR dapagliflozin OR canagliflozin OR ertugliflozin) AND (“Ascites”[Mesh] OR ascites OR “fluid retention” OR “refractory ascites”) AND (“Liver Cirrhosis”[Mesh] OR cirrhosis OR “hepatic cirrhosis”). Here, SLC5A2 is linked to Cirrhosis.